Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunoracle Inc. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and is situated within a distinct art unit, reflecting a concentrated effort in the pharmaceutical field. The company's current prosecution is focused on this active application. This approach allows the company to focus its resources on a specific advancement in biotechnology and pharmaceutical technology.
IVICH, FERNANDO NMN is the busiest examiner, overseeing the pending office action. This figure represents the entire pending workload for the company. Because the portfolio only has the pending office action, the prosecution strategy must be tailored to the specific feedback and standards of this examiner within the biotechnology domain. To advance the 1 pending office action, practitioners should focus on meeting the examiner's technical requirements while ensuring the company's pharmaceutical innovations are clearly defined.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704409 | METHODS OF ANALYZING A SAMPLE FOR CANCER-SPECIFIC IMMUNE CELLS | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704409 | METHODS OF ANALYZING A SAMPLE FOR CANCER-SPECIFIC IMMUNE CELLS | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704409 | METHODS OF ANALYZING A SAMPLE FOR CANCER-SPECIFIC IMMUNE CELLS | IVICH, FERNANDO NMN | 1678 | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunoracle Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fernando Nmn Ivich has the most, with 1 of Immunoracle Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
